glp 1 and chronic kidney disease GLP-1 agonists in the treatment of in type 2 diabetes obesity Unlocking Cardio-Renal Protection: Breakthrough with

Chang MG, Bittner EA

Furthermore, long-term studies focusing on safety, efficacy, and patient-specific factors will be essential to translate these innovations into viable therapeutic options

Some insurance plans may cover Wegovy if its prescribed to reduce heart disease-related risks in people who are overweight with heart disease or have obesity and heart disease

Giudicessi JR, Ackerman MJ, Camilleri M

GLP-1 RA-exposed pregnancies compared to matched control groups When estimating the Average Treatment Effect on the Treated (ATT), we did not observe any differences in birth weight, placental weight or the frequency of SGA or LGA, GDM or pre-eclampsia between GLP-1 RA exposure and any of the six control groups (Fig

This brief discusses the current landscape of Medicaid GLP-1 coverage and examines recent trends in Medicaid prescriptions and gross spending on GLP-1s